In agreement, we showed that the treatment of pterostilbene dose-dependently suppressed the percentage of CD133+ lung cancer cells in the presence of TAMs and that this effect was mediated by the concomitant downregulation of MUC1, NF-κB, β-catenin, Sox2, and CD133. This evidence concerns the gene NFKB1 and lung carcinoma.